Also trades as: BDXA (NYSE) · $vol 48M · BDXB (NYSE) · $vol 22M · 0R19.L (LSE) · $vol 0M · BDX.SW (SIX)
BDX NYSE
Becton, Dickinson and Company
1W: -3.8%
1M: -5.2%
3M: +13.7%
YTD: +15.4%
1Y: -6.9%
3Y: -28.7%
5Y: -23.1%
$176.80
-1.27 (-0.71%)
Weekly Expected Move ±3.5%
$164
$171
$177
$183
$189
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
18 relationships11
As Filer
counterparties named
7
As Counterparty
mentioned by others
2
Rel. Types
2021-08-13
Earliest Filing
2026-02-09
Latest Filing
partner: 10
acquirer: 1
Counterparties (Filed by BDX)
11 relationshipsCompanies named in BDX's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Waters Corporation | WAT | partner | Partner in spin-off and merger transaction acquiring Biosciences and Diagnostic Solutions business | 2026-02-09 | View |
| Augusta SpinCo Corporation | — | partner | Wholly owned subsidiary of Becton, Dickinson and Company used as the surviving entity in the merger | 2026-02-09 | View |
| Beta Merger Sub, Inc. | — | partner | Wholly owned subsidiary of Waters Corporation used as the merger subsidiary | 2026-02-09 | View |
| Waters Corporation | WAT | partner | Partner in a Reverse Morris Trust transaction to acquire BD's Biosciences and Diagnostic Solutions business. | 2025-07-14 | View |
| Augusta SpinCo Corporation | — | partner | Wholly owned subsidiary of BD created to hold the Biosciences and Diagnostic Solutions business for the transaction. | 2025-07-14 | View |
| Beta Merger Sub, Inc. | — | partner | Wholly owned subsidiary of Waters created to merge with Augusta SpinCo Corporation. | 2025-07-14 | View |
| Edwards Lifesciences Corporation | EW | acquirer | Target of BD's acquisition of Critical Care business | 2024-06-07 | View |
| Barclays Bank PLC | TAPR | partner | Underwriter for BD Notes and Becton Finance Notes offerings | 2021-08-13 | View |
| BNP Paribas | — | partner | Underwriter for BD Notes and Becton Finance Notes offerings | 2021-08-13 | View |
| Citigroup Global Markets Limited | — | partner | Underwriter for BD Notes and Becton Finance Notes offerings | 2021-08-13 | View |
| The Bank of New York Mellon Trust Company, N.A. | — | partner | Trustee for Becton Finance Indenture and BD Indenture | 2021-08-13 | View |
Mentioned As Counterparty
7 mentionsOther companies that named BDX in their SEC 8-K filings.
| Filed By | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|
| WAT WATERS CORP /DE/ | partner | Parent company of SpinCo; spun off Biosciences and Diagnostic Solutions business to Waters. | 2026-02-09 | View |
| WAT WATERS CORP /DE/ | partner | Parent company of SpinCo entering a Reverse Morris Trust transaction to spin off its Biosciences and Diagnostic Solution | 2025-07-14 | View |
| ANGO ANGIODYNAMICS INC | partner | Entered into a Settlement Agreement involving mutual patent licenses and financial payments to resolve litigation. | 2024-04-01 | View |
| EMBC Embecta Corp. | partner | Partner in Transition Services Agreement and Logistics Services Agreement amendments for interim business continuity pro | 2024-03-28 | View |
| STE STERIS plc | acquirer | Seller of surgical instrumentation, laparoscopic instrumentation, and sterilization containers platform assets acquired | 2023-06-20 | View |
| EMBC Embecta Corp. | partner | Counterparty in separation and distribution agreement for diabetes care business | 2022-04-06 | View |
| EMBC Embecta Corp. | target | Announced a spin-off distribution of 100% of Embecta's outstanding common stock to BD shareholders. | 2022-02-11 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-06 | Earnings Release; Exhibits | View | |
| 2026-07-22 | Officer/Director Change; Regulation FD; Exhibits | View | |
| 2026-05-29 | Regulation FD | View | |
| 2026-05-20 | Material Agreement; Financial Obligation; Exhibits | Agreement | View |
| 2026-05-12 | Other Events; Exhibits | View | |
| 2026-05-07 | Officer/Director Change; Regulation FD; Exhibits | View | |
| 2026-05-07 | Earnings Release; Exhibits | View | |
| 2026-04-29 | Bylaws Amendment; Exhibits | View | |
| 2026-04-09 | Officer/Director Change; Regulation FD; Exhibits | View | |
| 2026-04-02 | Earnings Release; Exhibits | View | |
| 2026-02-25 | Other Events; Financial Statements and Exhibits | View | |
| 2026-02-10 | Other Events; Financial Statements and Exhibits | View | |
| 2026-02-09 | Entry into Material Definitive Agreement; Departure/Election of Directors; Appointment of Officers; | Agreement | View |
| 2026-02-09 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-02-05 | Unregistered Sales of Equity Securities; Amendments to Articles of Incorporation or Bylaws; Financia | View | |
| 2026-02-05 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2026-01-30 | Departure/Election of Directors; Appointment of Officers; Submission of Matters to a Vote of Securit | View | |
| 2026-01-06 | Temporary Suspension of Trading Under Employee Benefit Plan | View | |
| 2025-12-01 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2025-11-17 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR